Feds Crack Down on TV Drug Ads, in Major Shakeup to Pharma Industry

The era of direct-to-consumer (DTC) pharmaceutical commercials may be coming to a close.

On September 9, President Donald Trump signed a memorandum ordering the Food and Drug Administration (FDA) to increase enforcement of restrictions on DTC drug advertising, with an emphasis on TV ads. The FDA announced a crackdown on “deceptive” DTC ads that same day.

“For far too long these ads have distorted the doctor-patient relationship and have created artificial demand for induction regardless of their clinical appropriateness,” FDA Commissioner Marty Makary stated on social media. “In recent years the FDA has increasingly been lax in its enforcement approach … Well, it’s a new day.”

The FDA has already issued approximately 100 cease-and-desist letters, and thousands of additional warning letters. These actions are being heavily promoted by the administration, and framed as a corrective to the dwindling number of letters the FDA has been issuing in recent years. However, it doesn’t appear that the agency actually sent companies individualized letters describing specific violations identified in their advertising. The letter authored by Makary and shared by the FDA begins “Dear Pharmaceutical Company,” and includes the line “We are issuing this letter to provide notice to all application holders.” Cease-and-desist letters are not typically issued in this generic fashion.

The FDA has a certain amount of enforcement authority under the Federal Food Drug and Cosmetic Act, which requires that all prescription drug advertising balance information about potential benefits with information about potential risks, so as to not be misleading. But the administration is not banning DTC ads outright—something Health and Human Services Secretary Robert F. Kennedy Jr. has pushed for, but which federal courts have historically viewed as a violation of the First Amendment, and which the FDA has stated it doesn’t have the authority to do.

Let’s get President Trump back in the White House and me to DC so we can ban pharmaceutical advertising. pic.twitter.com/Qp7fj9xskU

— Robert F. Kennedy Jr (@RobertKennedyJr) November 3, 2024

TV ads hawking pharmaceuticals to potential patients is essentially an American phenomenon; only New Zealand has comparably permissive regulations.

Up until the 1980s, pharma companies would pitch their products to health care providers, who were the sole source of information for patients. Then companies realized they could bypass the medical professionals, and advertise to the public directly. 

In 1985 the FDA issued guidelines that restricted pharmaceutical ads, including by banning them from naming specific conditions that a drug could treat, unless they also included the complete list of side effects. Newspapers and magazines were able to accommodate this requirement, but the concept of “fine print” doesn’t translate as well to TV and radio. Many companies didn’t bother. 

Then, in 1997, the FDA issued new guidelines. Rather than list all the side effects, ads only needed to include a brief summary. Or, instead of the brief summary, a URL or toll-free number viewers could use to find the information. This became known as the “adequate provision” loophole. The pharmaceutical industry now spends over $5 billion a year on TV advertising, and over $10 billion a year on DTC ads in total.

“The Trump administration is taking action to return to the pre-1997 status quo by engaging in FDA rule-making to close the ‘adequate provision’ loophole to ensure risk disclosure,” HHS stated, ”and stepping up enforcement action of DTC pharmaceutical ads.”

RFK Jr. has suggested the changes might result in ads that swell to four minutes long, in order to include all the side effects and required risk information. The likelihood of this is unclear, but what seems more certain is that pharma companies will file legal challenges to the new restrictions.

“Pharmaceutical ads hooked this country on prescription drugs,” RFK Jr. stated. “We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America’s chronic disease epidemic.”

In 2019 during his first presidential term, Trump attempted to force pharma companies to include drug prices in their DTC commercials, if the price would be more than $35 per month. A federal judge blocked it in the final hours before it would have taken effect, ruling that the administration doesn’t have the legal authority to compel private companies to disclose their prices.

Image (cropped) via United States Food and Drug Administration/YouTube

No Byline Policy

Editorial Guidelines

Corrections Policy

Source